Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION ...

| --- | --- | |-------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------| | | | | Date & Time Eftilagimod | : Wednesday, April 3, 2019, 7:45am Australian Eastern Standard Time Alpha Clinical Development Update and New Data from Ongoing Melanoma Study | | Register | Tuesday, April 2, 2019, 4:45pm US Eastern Daylight Time : Interested investors can register via the following link to the webcast we ...

| --- | --- | --- | |-------|-------|-------| | | | | | | | | | | | | | | | | Notice: Forward Looking Statements The purpose of the presentation is to provide an update of the business of Immutep Limited ACN 009 237 889 (ASX:IMM; NASDAQ:IMMP). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcement ...